Addressing Preclinical Gaps in Biotech Trials
To prevent delays in biotech trials, it's crucial to address preclinical gaps and ensure early toxicology readiness. Strong scientific collaboration with CRO partners is also vital for accelerating trial startup and regulatory approval.
Ben Edwards, chief operating officer at Avance Clinical, emphasizes the importance of addressing preclinical package gaps to avoid delays.
Key factors in preventing delays include working with CROs that have deep scientific capabilities, obtaining patient data early, and utilizing adaptive trial designs. Effective coordination across functions requires integrated teams and data visualization.
Author's summary: Accelerate biotech trials by addressing preclinical gaps.
- Early toxicology readiness is critical
- Strong scientific collaboration with CRO partners is essential
- Obtaining patient data early informs decision-making
- Adaptive trial designs offer benefits
- Integrated teams and data visualization ensure effective coordination
More News
- Who won fashion month SS26 on social media?
- Platforms of Extremism: Why Australia Must Confront Digital Misogyny as a Security Threat - Australian Institute of International Affairs
- Armenians in Jerusalem and the dilemma of Israel's recognition of the Armenian Genocide
- Mount Pleasant residents urge town council for speed humps after near-miss incident
- Why the Reckoning Is a Historian's Protest - CEOWORLD magazine
- Chicago Catholics confront ICE, fear and protests to protect migrants' dignity, religious rights - Catholic Standard
- Kada Scott: Arrest made in disappearance of 23-year-old Philadelphia woman as search continues
- Growing fallout over 'Young Republican' chat leak
- Chattanooga residents frustrated by brush pickup delays amid 311 backlog
- Historian tells how Colorado Springs became ‘evangelical Vatican’ – Baptist News Global